XML 34 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Unaudited Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended 10 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Net revenue     $ 26,115,000 $ 23,054,000   $ 31,317,000 $ 23,560,000 $ 21,033,000
Operating costs and expenses:                
Cost of revenue     6,284,000 2,549,000   3,634,000 2,149,000 5,802,000
Research and development     6,457,000 7,031,000   9,201,000 9,961,000 10,216,000
Acquired in-process research and development           0 0 75,301,000
Selling, general and administrative     41,371,000 36,092,000   50,582,000 42,970,000 64,696,000
Intangible amortization     2,896,000 2,803,000   3,738,000 3,738,000 3,713,000
Total operating costs and expenses     57,008,000 48,475,000   67,155,000 58,818,000 159,728,000
Loss from operations     (30,893,000) (25,421,000)   (35,838,000) (35,258,000) (138,695,000)
Other income (expense):                
Gain on derivative liability     (5,300,000) (100,000)   300,000 (800,000) 23,300,000
(Gain) loss on debt extinguishment, net     (28,634,000) 12,463,000   12,463,000 0 0
Scilex Pharma Notes principal increase           28,000,000 0 0
Interest expense     (8,596,000) (8,617,000)   (11,764,000) (13,116,000) (16,889,000)
Interest income           0 0 (460,000)
(Gain) loss on foreign currency exchange     (39,000) 48,000   54,000 (2,000) 168,000
Total other (income) expense     (25,377,000) 21,028,000   52,581,000 12,314,000 39,897,000
Loss before income taxes     (5,516,000) (46,449,000)   (88,419,000) (47,572,000) (178,592,000)
Income tax (benefit) expense     (36,400) 10,000   5,000 (53,000) 2,000
Net loss     $ (5,480,000) $ (46,459,000)   $ (88,424,000) $ (47,519,000) $ (178,594,000)
Basic net (loss) income per share, ordinary shares (in Dollars per share)     $ (0.03) $ (0.24)   $ (0.45) $ (0.24) $ (0.95)
Diluted net (loss) income per share, ordinary shares (in Dollars per share)     $ (0.03) $ (0.24)   $ (0.45) $ (0.24) $ (0.95)
Weighted average shares outstanding, ordinary shares (in Shares) , Basic     197,550 197,266   197,266 197,315 187,524
Weighted average shares outstanding, ordinary shares (in Shares) , diluted     197,550 197,266   197,266 197,315 187,524
Vickers Vantage [Member]                
Operating costs and expenses:                
Total operating costs and expenses $ 657,746 $ 283,346 $ 2,412,297 $ 620,642 $ 6,276 $ 1,005,498    
Loss from operations (657,746) (283,346) (2,412,297) (620,642) (6,276) (1,005,498)    
Other income (expense):                
Change in fair value of warrants         4,377,600    
Change in fair value of warrant liability 68,400 (1,162,800) 2,188,800 2,872,800 4,377,600    
Loss on initial issuance of private warrants 0 0 0 (2,599,200) (2,599,200)    
Transaction costs allocated to warrant liabilities 0 0 0 (30,212) (30,212)    
Change in fair value of conversion option liability 0 0 6,892 0   11,835    
Interest on mandatorily redeemable ordinary shares liability 0 0 192,049 0        
Income earned on investments held in Trust Account 459,114 1,794 664,973 28,006 30,739    
Interest expense (1,155) 0 (16,901) 0   (1,826)    
Total other (income) expense 526,359 (1,161,006) 3,035,813 271,394 1,788,935    
Net loss $ (131,387) $ (1,444,352) $ 623,516 $ (349,248) $ (6,276) $ 783,438    
Basic net (loss) income per share, ordinary shares (in Dollars per share) $ (0.01) $ (0.08) $ 0.04 $ (0.02) $ 0 $ 0.05    
Diluted net (loss) income per share, ordinary shares (in Dollars per share) $ (0.01) $ (0.08) $ 0.04 $ (0.02) $ 0 $ 0.05    
Weighted average shares outstanding, ordinary shares (in Shares) , Basic 13,176,395 17,250,000 15,862,288 16,675,824 3,000,000 [1] 16,820,548 [1]    
Weighted average shares outstanding, ordinary shares (in Shares) , diluted 13,176,395 17,250,000 15,862,288 16,675,824 3,000,000 16,834,110    
[1] At December 31, 2020, excludes an aggregate of up to 450,000 ordinary shares that were subject to forfeiture.